Non-coding DNA variants contribute to acute lymphoblastic leukemia (ALL) chemotherapy resistance. St. Jude Children's Research Hospital scientists have identified specific DNA variants in the ...

Researchers announced a significant paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of cancer, to one frequently driven by ...

For decades, scientists have been puzzled by large portions of the human genome labeled as “junk” DNA, sequences that seemingly serve no purpose. Yet, recent studies suggest these cryptic sequences ...

Recent scientific breakthroughs have transformed the once-dismissed non-coding DNA, or “junk DNA,” into a targeted weapon against cancer. Leveraging artificial intelligence, scientists have uncovered ...

Only around two percent of the human genome codes for proteins, and while those proteins carry out many important functions of the cell, the rest of the genome cannot be ignored. However, for decades ...

Researchers have developed a method to swiftly screen the non-coding DNA of the human genome for links to diseases that are driven by changes in gene regulation. The technique could revolutionize ...

The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark ...

The human genome contains about 20,000 protein-coding genes, but that only accounts for roughly two percent of the genome. For many years, it was easier for scientists to simply ignore all of that ...

(L to R) Co-first author Jackson Mobley, PhD, corresponding author Daniel Savic, PhD, and co-first author Kashi Raj Bhattarai, PhD, all of the St. Jude Department of Pharmacy and Pharmaceutical ...

Researchers at Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG) today announced a significant paradigm shift in the ...